TOBAM’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.89M | Buy |
10,875
+1,960
| +22% | +$1.1M | 1.43% | 21 |
|
|
2026
Q1 | $5.29M | Sell |
8,915
-942
| -10% | -$469K | 1.38% | 24 |
|
|
2025
Q4 | $4.8M | Buy |
9,857
+2,211
| +29% | +$1.03M | 1.18% | 30 |
|
|
2025
Q3 | $3.21M | Buy |
7,646
+4,953
| +184% | +$1.67M | 1.16% | 34 |
|
|
2025
Q2 | $774K | Sell |
2,693
-3,695
| -58% | -$1.1M | 0.3% | 69 |
|
|
2025
Q1 | $1.97M | Sell |
6,388
-11,834
| -65% | -$4.06M | 0.84% | 43 |
|
|
2024
Q4 | $6.43M | Sell |
18,222
-19,719
| -52% | -$7.25M | 1.96% | 13 |
|
|
2024
Q3 | $13.6M | Sell |
37,941
-18,317
| -33% | -$6.19M | 2.48% | 4 |
|
|
2024
Q2 | $17.9M | Sell |
56,258
-52,389
| -48% | -$13.9M | 2.81% | 3 |
|
|
2024
Q1 | $25M | Sell |
108,647
-5,110
| -4% | -$1.15M | 2.24% | 17 |
|
|
2023
Q4 | $25M | Sell |
113,757
-31,663
| -22% | -$7.3M | 2.19% | 18 |
|
|
2023
Q3 | $32.8M | Sell |
145,420
-3,073
| -2% | -$708K | 2.64% | 9 |
|
|
2023
Q2 | $32.8M | Sell |
148,493
-21,430
| -13% | -$4.75M | 2.47% | 11 |
|
|
2023
Q1 | $38.1M | Buy |
169,923
+60,639
| +55% | +$14.9M | 2.51% | 9 |
|
|
2022
Q4 | $30.4M | Buy |
109,284
+67,767
| +163% | +$17.1M | 2.01% | 16 |
|
|
2022
Q3 | $8.69M | Buy |
41,517
+37,750
| +1,002% | +$8.44M | 0.61% | 54 |
|
|
2022
Q2 | $888K | Buy |
+3,767
| New | +$766K | 0.06% | 136 |
|
|
2019
Q1 | – | Sell |
-17,080
| Closed | -$1.86M | – | 160 |
|
|
2018
Q4 | $1.86M | Sell |
17,080
-18,915
| -53% | -$2.19M | 0.09% | 103 |
|
|
2018
Q3 | $4.6M | Sell |
35,995
-8,157
| -18% | -$1.01M | 0.2% | 89 |
|
|
2018
Q2 | $5M | Buy |
44,152
+8,874
| +25% | +$975K | 0.21% | 89 |
|
|
2018
Q1 | $3.96M | Buy |
35,278
+3,035
| +9% | +$386K | 0.16% | 100 |
|
|
2017
Q4 | $4.77M | Sell |
32,243
-35,156
| -52% | -$4.47M | 0.21% | 89 |
|
|
2017
Q3 | $7.9M | Sell |
67,399
-356
| -0.5% | -$45.5K | 0.3% | 78 |
|
|
2017
Q2 | $8.79M | Buy |
67,755
+8,820
| +15% | +$1.1M | 0.33% | 66 |
|
|
2017
Q1 | $7.98M | Sell |
58,935
-14,528
| -20% | -$2.2M | 0.31% | 69 |
|
|
2016
Q4 | $10.5M | Sell |
73,463
-53,984
| -42% | -$6.89M | 0.43% | 60 |
|
|
2016
Q3 | $15M | Buy |
127,447
+59,275
| +87% | +$7.12M | 0.54% | 56 |
|
|
2016
Q2 | $7.22M | Sell |
68,172
-31,239
| -31% | -$3.48M | 0.29% | 62 |
|
|
2016
Q1 | $11.1M | Sell |
99,411
-54,648
| -35% | -$6.92M | 0.44% | 59 |
|
|
2015
Q4 | $24.1M | Sell |
154,059
-22,314
| -13% | -$3.25M | 1.04% | 32 |
|
|
2015
Q3 | $23.1M | Sell |
176,373
-71,693
| -29% | -$11.5M | 0.9% | 40 |
|
|
2015
Q2 | $43.1M | Buy |
+248,066
| New | +$44.6M | 1.57% | 22 |
|
Other funds holding UTHR
ACA
JT
TOBAM's UTHR Position: Q2 2026 in Review
TOBAM increased its United Therapeutics (UTHR) stake by 22% in Q2 2026, buying an estimated $1.1M and bringing the position to 10,875 shares worth $5.89M. The position accounts for 1.43% of the portfolio, ranked #21.
TOBAM first reported a position in UTHR in Q2 2015 and has held it in 32 quarters since. The position peaked at $43.1M in Q2 2015. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- TOBAM held 10,875 shares of United Therapeutics worth $5.89M as of Q2 2026.
- TOBAM bought 1,960 United Therapeutics shares in Q2 2026, an estimated $1.1M.
- United Therapeutics made up 1.43% of TOBAM's portfolio in Q2 2026, its #21 holding.
- TOBAM first reported a position in United Therapeutics in Q2 2015 and has held it in 32 quarters since.
- TOBAM's United Therapeutics position peaked at $43.1M in Q2 2015.
- 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on TOBAM's 13F filing for Q2 2026, filed 31 Jul 2026.